Cipla | CIPLA - Current Liabilities


Cipla reported INR70.14B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Arca Biopharma USD 16.63M 1.26M Mar/2026
aTyr Pharma USD 11.7M 101.49M Mar/2026
Bio Path USD 9.15M 468K Mar/2026
Brainstorm Cell Therapeutics USD 11.76M 757K Mar/2026
Capricor Therapeutics USD 33.64M 2.2M Mar/2026
Cara Therapeutics USD 11.04M 2K Dec/2025
Cipla INR 70.14B 7.16B Mar/2026
Dr.Reddys Laboratories INR 167.47B 9.16B Mar/2026
Esperion Therapeutics USD 300.36M 451K Mar/2026
Immunic USD 38.36M 7.74M Mar/2026
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sun Pharmaceuticals INR 226.22B 7.93B Mar/2026
TherapeuticsMD USD 5.82M 655K Jun/2024
UPL INR 347.48B 16.58B Mar/2026